Comparing Manufacturer Submitted and Pan-Canadian Oncology Drug Review Reanalysed Incremental Cost-Effectiveness Ratios for Novel Oncology Drugs

Background: To determine the magnitude of difference between manufacturer-submitted and pan-Canadian Oncology Drug Review (pCODR) calculated incremental cost-effectiveness ratios (ICERs), incremental cost (ΔC), and incremental effectiveness (ΔE); to examine whether there is a significant difference...

Descripción completa

Detalles Bibliográficos
Autores principales: Saluja, Ronak, Jiao, Tina, Koshy, Liza, Cheung, Matthew, Chan, Kelvin K. W.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: MDPI 2021
Materias:
Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7924399/
https://www.ncbi.nlm.nih.gov/pubmed/33498460
http://dx.doi.org/10.3390/curroncol28010060

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7924399/
https://www.ncbi.nlm.nih.gov/pubmed/33498460
http://dx.doi.org/10.3390/curroncol28010060

Ejemplares similares